Oppenheimer is out with its report today on Stericycle SRCL, maintaining Outperform.
In its report, Oppenheimer writes, "We're reiterating our Outperform rating and $100 price target, which is based on 31x our likely conservative 2012 EPS estimate of $3.22. Stericycle currently trades at 26x our 2012 EPS estimate, which is below the company's 5-year historical average forward multiple of 28x (range of 21x-38x). The stock is down more than 8% August-to date, which compares to the broader market (S&P 500) down just one more percentage point over the same
period."
Shares of SRCL closed Wednesday at $84.41, up 0.91% from Tuesday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in